Grace Halsey

The reductions observed in all-cause mortality (49%) and MACE (39%) in high-risk patients compared with statin monotherapy could be practice changing, researchers said.

AAD 2025: Raj Chovatiya, MD, PhD, MSCI, well-known physician scientist, says underrepresentation in clinical trials of those with skin of color precludes an evidence-based answer.

In a small study of adults genetically predisposed to early-onset dementia, anti-amyloid treatment to remove plaque reduced risk of developing symptoms by 50%.

The greatest risk for developing cancer faces residents of South Dakota, where radon levels are the nation's highest, and ranks for alcohol consumption and obesity are poor.

The IL-23 inhibitor is the only drug in the class available with both subcutaneous and intravenous administration options for treatment induction, according to J&J.

Raj Chovatiya, MD, PhD, MSCI, discusses the complex and widely variable influences that affect the manifestations and burden of atopic dermatitis across populations.

AAD 2025: Chovatiya discusses whether melanin concentration plays a role in skin physiology and cautioned against typing with factors that are not true biologic constructs.

In individuals with skin of color with AD, lebrikizumab was associated with improved QoL and importantly with high rates of patient-reported treatment satisfaction.

The amylin analog at 5 doses will be compared with placebo when added to a reduced calorie diet and increased physical activity regimen for 42 weeks, said Zealand Pharma.

Chovatiya, expert clinical dermatologist and researcher, points out that the term "skin of color" comprises a heterogenous set of topics, in an interview at AAD 2025.

Among pediatric patients aged 1 month to 18 years with emergent anaphylaxis, cephalosporins were the leading antibiotics and ibuprofen the top NSAID implicated in a new study.

Three of the 5 osteoporosis screening tools recommended by the USPSTF for identifying osteoporosis in postmenopausal women aged 50 yo 64 years proved suboptimal.

Antihistamines for itch caused by disorders like atopic dermatitis pose more problems, like sedation and fall risk, than they provide relief, according to Daniel Butler, MD.

Both trials met their primary endpoints, demonstrating a statistically significant improvement in HiSCR50 compared to placebo, with a favorable safety profile, according to Incyte.

A new study compared health care utilization and costs between adults initially misdiagnosed followed by a correct diagnosis of migraine and those whose first diagnosis was accurate.

AAD 2025: Tracing the multiple pathways that contribute to chronic itch vs looking for a singular cause helps optimize choice of therapy, Butler says.

A new economic evaluation estimates that semaglutide would need to drop its current price by 81.9% and tirzepatide by 30.5% to be cost effective.

Improvement in AD signs and symptoms continued through 56 weeks of treatment with the PDE4 inhibitor including when used just twice weekly as prophylaxis.

Dupilumab-treated participants with recalcitrant head and neck symptoms who were switched to upadacitinib rapidly reached EASI 75 and steadily improved, among other findings.

Positive findings for postsurgical acute pain relief from the pivotal phase 3 ALLEVIATE-2 trial complete the development program, allowing plans for NDA submission.

Higher levels of cardiovascular health were associated with lower levels of neurofilament light chain across age, sex, race/ethnicity, and Alzheimer disease risk.

Elinzanetant, a first in class dual neurokinin-1 and 3 (NK-1,3) receptor antagonist in late-stage clinical development, has a US PDUFA date set for July 26, 2025.

Analysis of data from the donanemab TRAILBLAZER development program underscores the essential role of patient selection and treatment monitoring.

Brian S Kim, MD, a leading investigator in the study of itch physiology, discusses the marked progress made in understanding the sensation and targeting its treatment.

The impact of childhood onset AD on adult psychosocial experience is far reaching and profound according to findings from the Scars of Life Survey.

The impact of childhood onset AD on adult psychosocial experience, including employment and the decision to become a parent, is profound, this study reveals.

The menopausal symptom and lifestyle management app provides guideline-based CBT principles to augment hormone therapy or even to replace it for some women.

CagriSema proved superior to placebo in the pivotal phase 3 trial but as in the earlier REDEFINE 1 study fell short of the 25% or greater reduction Novo Nordisk projected.

AAD 2025. Guttman, among the world's foremost researchers in dermatology, toplined how far the field has come in her "Hot Topics" presentation on the final day of the 2025 AAD.

Data on delgocitinib from the DELTA development program highlight efficacy of the topical JAK inhibitor for treatment of chronic hand eczema.